Cortical Activity and Gait Function for Robotic Gait Training in Hemiparetic Stroke

Sponsor
National Rehabilitation Center, Seoul, Korea (Other)
Overall Status
Completed
CT.gov ID
NCT04054739
Collaborator
(none)
30
1
2
16
1.9

Study Details

Study Description

Brief Summary

Effects of robot-assisted gait training on cortical activity and gait function in hemiparetic stroke

Condition or Disease Intervention/Treatment Phase
  • Device: Robot-assisted gait training
  • Device: Treadmill gait training
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Effects of Robotic Gait Training on Cortical Activity and Gait Function in Hemiparetic Stroke
Actual Study Start Date :
Sep 1, 2018
Actual Primary Completion Date :
Nov 30, 2019
Actual Study Completion Date :
Dec 31, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Robot-assisted gait training

experimental group that applied the end-effector robot-assisted gait training

Device: Robot-assisted gait training
intervention with robot-assisted gait training

Active Comparator: Treadmill gait training

control group that applied the treadmill gait training

Device: Treadmill gait training
intervention with treadmill gait training

Outcome Measures

Primary Outcome Measures

  1. oxygenated hemoglobin levels [4 weeks from baseline]

    cortical activity of primary sensorimotor cortex, premotor cortex, supplementary motor areas, pre-supplementary motor areas, prefrontal cortex during gait

  2. Range of motion of ankle, knee, and hip joint [4 weeks from baseline]

    ankle, knee, and hip joint motion of sagittal plane during gait

Secondary Outcome Measures

  1. oxygenated hemoglobin levels [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    cortical activity of primary sensorimotor cortex, premotor cortex, supplementary motor areas, pre-supplementary motor areas, prefrontal cortex during gait

  2. Range of motion of ankle, knee, and hip joint [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    ankle, knee, and hip joint motion of sagittal plane during gait

  3. Berg Balance Scale [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    Berg Balance Scale assess the functional balance ability of participants with observation of 14 tasks, representing functional movements common in daily life. Each task is scored on a five-point scale (0-4) following the guidelines of the test developers, and the maximum score on this test is 56 which indicates balance ability within the normal range.

  4. Fugl-Meyer Assessment [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    Fugl-Meyer Assessment uses to examine the motor function and coordination of affected lower extremity. It includes 17 items of a 3-point ordinal scale, ranging 0-34, with higher scores indicating lower impairment.

  5. 10m walk test [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    10m walk test is used to examine gait speed, in which participant was asked to walk on a 14 meter of walkway wearing harness with two conditions; with the fastest speed or with self-selected comfortable speed.

  6. Functional ambulation category [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    Functional Ambulation Category is used to assess gait ability with 6 levels ranging from 0 to 5 on the basis of the amount of physical support required, regardless of use of an assistive device

  7. Falls efficacy scale [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    Korean version of Falls efficacy scale asks subjects to rank their confidence about their ability not to fall while performing a variety of activities of daily living with a maximum score of 100

  8. Beck depression inventory [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    21-question multiple-choice self-report inventory, one of the most widely used psychometric tests

  9. Stroke impact scale [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    health-related quality of life poststroke across 8 domains using a 5-point Likert scale, with the score ranging from 0 to 100 and a higher score indicating better health status

  10. Dynamic gait index [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    a clinical tool to assess gait, balance and fall risk

  11. Timed up and go test [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    a simple test used to assess a person's mobility and requires both static and dynamic balance

  12. modified Barthel index [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    Measure of physical disability used widely to assess behaviour relating to activities of daily living for stroke patients

  13. dual task - COWAT [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    Controlled Oral Word Association Test, abbreviated COWA or COWAT, is a verbal fluency test that measures spontaneous production of words belonging to the same category or beginning with some designated letter.

  14. dual task - digit span test [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    The digit span test is a way of measuring the storage capacity of a person's working memory.

  15. Electromyography of lower extremities [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    Muscle activity of tibialis anterior, medial gastrocnemius, vastus medialis, biceps femoris, gluteus medius during gait.

  16. Plantar pressure [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    Plantar pressure (great toe, little toe, medial meta, lateral meta, medial arch, lateral arch, heel) during gait

  17. Spatiotemporal gait parameter data [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    step length, step time, swing time, double limb support time during gait

  18. deoxygenated hemoglobin levels [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    cortical activity of primary sensorimotor cortex, premotor cortex, supplementary motor areas, pre-supplementary motor areas, prefrontal cortex during gait

  19. total hemoglobin levels [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    cortical activity of primary sensorimotor cortex, premotor cortex, supplementary motor areas, pre-supplementary motor areas, prefrontal cortex during gait

  20. Balance test using force plate [baseline, 2 weeks after baseline, 4 weeks after baseline, 8 weeks after baseline]

    Static standing balance as measured using a force plate: Changes in center-of-pressure velocity and area

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Hemiplegic patients secondary to first cerebrovascular accidents

  • Functional ambulation category score 3

  • 3 months ≤ Onset ≤ 12 months

  • Korean Mini-Mental State Examination score > 24

Exclusion Criteria:
  • History of surgery of affected lower limb

  • Fracture of affected lower limb

Contacts and Locations

Locations

Site City State Country Postal Code
1 National Rehabilitation Center Seoul Korea, Republic of 142884

Sponsors and Collaborators

  • National Rehabilitation Center, Seoul, Korea

Investigators

  • Principal Investigator: Joon-Ho Shin, MS, National Rehabilitation Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Joon-Ho Shin, Team manager, National Rehabilitation Center, Seoul, Korea
ClinicalTrials.gov Identifier:
NCT04054739
Other Study ID Numbers:
  • NRC-2017-02-015
First Posted:
Aug 13, 2019
Last Update Posted:
Feb 11, 2020
Last Verified:
Feb 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Joon-Ho Shin, Team manager, National Rehabilitation Center, Seoul, Korea
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 11, 2020